Lilly Medical - Search News

Eli Lilly, Zepbound

MarketWatch on MSN · 4h

Eli Lilly’s stock rises as Zepbound weight-loss drug achieves a key goal

Eli Lilly & Co. Inc.’s stock rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study. Zepbound achieved an average weight loss of 20.

USA Today · 5h

Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.

ConsumerAffairs · 5h

Eli Lilly claims superiority of its weight-loss drug Zepbound after clinical trial

Drugmaker Eli Lilly is claiming victory in the battle of weight loss drugs, now one of the most competitive and lucrative areas of the pharmaceutical indus

5h

Lilly's tirzepatide challenges semaglutide in obesity drug market

The trial enrolled 751 adults with obesity or overweight conditions and at least one weight-related medical problem ...

Pfizer, Eli Lilly execs push back as senators scrutinize drugmakers’ telehealth moves

Pharma vs pushes back as Senators look into telehealth moves, startups using AI for small molecule drugs, and more.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results